Month four is usually when it starts. You're down thirty pounds, your knees quit complaining, your labs came back better than they have in a decade, and you're standing in the shower holding a wad of your own hair, doing math you'd rather not do.
The timing feels like a smoking gun. Hair grows on a long delay, though, and whatever set this off was most likely happening back around month one, when you were too busy being nauseous to notice.
The Quick Answer
Hair loss is a reported side effect of both drugs, and it is usually temporary. On the semaglutide weight-management label, hair loss was reported by 3% of treated adults versus 1% on placebo.1 On the tirzepatide label it was 5% at the 5 mg dose, 4% at 10 mg, and 5% at 15 mg, against 1% on placebo, and the label states that hair loss in treated patients was associated with weight reduction.2 That same label breaks the figure out by sex: 7.1% of women versus 0.5% of men.2 The pattern is consistent with telogen effluvium, a reversible shedding response to metabolic stress that typically begins about three months after the trigger and resolves within six months.3
What the Labels Actually Say
Most of this sits in a side-effects table in a document written for pharmacists. Here's the table.
| Placebo | Treated | |
|---|---|---|
| Semaglutide 2.4 mg weekly (N=2,116 treated, 1,261 placebo) | 1%1 | 3%1 |
| Tirzepatide 5 mg (N=630) | 1%2 | 5%2 |
| Tirzepatide 10 mg (N=948) | 1%2 | 4%2 |
| Tirzepatide 15 mg (N=941) | 1%2 | 5%2 |
A few things jump out. The placebo groups shed too, at 1%, which means some of what people blame on the drug was going to happen regardless. And in the tirzepatide trials, not one person on the drug quit over it. The label notes that no tirzepatide-treated patients discontinued due to hair loss, while one placebo-treated patient did.2
The two labels also treat the subject very differently. Semaglutide's lists hair loss in the table without further comment.1 Tirzepatide's gives it a named subsection and explains what the trials saw.2
The Number That Refuses to Behave
Run your eye down the tirzepatide column one more time. Five percent, then four, then five, while the dose triples from 5 mg to 15 mg.
That line should climb. Real drug side effects usually do. Vomiting on the same label behaves itself perfectly, marching from 8% to 11% to 13% as the dose goes up.2 Hair loss just sits there, flat as a parking lot, indifferent to how much tirzepatide is in you.
So the label says the quiet part out loud. Hair loss in treated patients "was associated with weight reduction."2 The mechanism is the weight loss itself. The drug drives fast weight loss, and fast weight loss is what your hair objects to.
Which, if you've been anywhere near a diet in the last fifty years, should sound familiar. The standard clinical reference on this kind of shedding lists crash dieting and low protein intake right alongside major surgery, childbirth, high fever, and iron deficiency as classic triggers.3 Not a GLP-1 among them. People who dropped forty pounds on cabbage soup in 1993 were pulling hair out of their brushes too. They just didn't have a prescription to blame.
The Fourteen-Fold Gap
The biggest split in this data is between men and women, and it's not close.
In the pooled tirzepatide weight-reduction trials, 7.1% of women on the drug reported hair loss. For men it was 0.5%. In the placebo groups, 1.3% of women and zero men.2
Some of that is biology. Women are more prone to this type of shedding in general, largely through hormonal triggers like the estrogen drop after childbirth.3 Some of it is that shedding is simply easier to see on long hair, and the same fifty strands that vanish unnoticed down a man's drain form a visible, horrifying little nest on a woman's. And some of it is that women are more likely to be bothered enough to tell a doctor, which is the only way anything gets into a trial's adverse event column in the first place.3 The trials can't pull those three apart.
If you're a woman starting one of these programs, knowing this in month one beats discovering it in month four and concluding something has gone badly wrong.
What's Happening Up There
Your scalp runs on shifts. Roughly 85% of your hair is actively growing at any moment, and about 15% is resting.3 A follicle typically works for close to four years straight, clocks out for around four months, then a new hair grows in underneath and shoves the old one out the door.
That's the normal churn. You lose some hair every single day and never think about it.
Now put the body under real physiologic stress, which a fast thirty-pound loss qualifies as. Instead of a trickle of follicles clocking out on their own schedule, as much as 70% of your growing hair can be sent off-shift all at once.3
Those hairs don't fall out when they clock out. They stay put, doing nothing, for one to six months, averaging about three.3 You see nothing. You feel nothing. You get on with your life. The shedding only happens later, when the follicle fires back up and the new hair physically pushes the old one loose.3
Which means the hair in your hand is the sound of follicles restarting. It's a strange thing to be glad about. It's also true, and there's no scarring involved: the follicle count on your head stays exactly what it was.3
Why the Blame Always Lands Late
Stack those two facts and the whole thing snaps into focus. The trigger and the shedding are separated by roughly three months, with a range of one to six.3 The clinical text notes that patients have usually recovered from the triggering event completely and don't connect it to their hair at all.3
On a weight loss program it plays out like clockwork. The sharpest part of the calorie drop happens in the first six or eight weeks, back when eating felt like a chore. The shedding arrives somewhere around month three to five, when you feel terrific and the scale is behaving, which is precisely when it makes the least sense.
A few numbers to keep in mind:
- Acute telogen effluvium lasts under six months by definition, and the shedding stretch is often much shorter.3
- Collecting 100 or more hairs over 24 hours, without washing, points toward telogen effluvium rather than normal turnover.3
- Regrowth can take up to six months just to restart, and longer before you can see it in the mirror.3
- The condition is benign and spontaneously reversible, and the expected outcome is recovery of hair density.3
What Actually Helps
The real advice here is boring, which is why nobody sells it.
Eat enough, and eat enough protein. Low protein intake and crash dieting are named triggers.3 Your appetite falls off a cliff on these medications, and people routinely end up eating half the protein they think they are without ever making a decision to. Our guide to what to eat on a GLP-1 covers the protein-first approach, and it exists for muscle reasons long before hair enters the conversation.
Slow the curve. If the shedding tracks how fast the weight comes off, then how fast the weight comes off is the lever. That's a large part of why our protocol titrates in small bi-weekly steps instead of monthly jumps. Do not go adjusting your own dose because of a blog post, this one included. If the pace worries you, that's a message to your provider, not a decision to make in your bathroom.
Check the things that are actually checkable. The standard reference recommends testing for iron deficiency and thyroid dysfunction when someone is shedding, and notes that correcting low iron, zinc, or vitamin D restores growth when one of those is the culprit.3 Two details worth knowing before you get labs back: low ferritin confirms iron deficiency, but normal ferritin doesn't rule it out, because ferritin climbs with inflammation and can mask a real shortage. Iron saturation is the more sensitive marker.3
Wait. Most cases resolve on their own once the trigger passes.3
What You Can Skip
The clinical reference is refreshingly blunt about treatment. If the cause has been identified and dealt with, nothing further is needed, and prescribing hair growth medications or sending someone for a transplant is unnecessary.3
On minoxidil it's careful in a way that's easy to misread. Topical minoxidil has not been proven to promote hair recovery in telogen effluvium, though it has theoretical benefits, and patients who want to take an active role may choose to use it.3
Then there are the supplements, which are where most of the money goes and the least happens. The deficiencies that reference names as worth fixing are iron, zinc, and vitamin D.3 Biotin is not on the list. Topping up a nutrient you already have enough of does very little.
And frankly, the hair-vitamin business is built on the three-month delay. Start a gummy at the peak of your shedding, keep shedding for another six weeks, then watch it stop on the exact schedule it was always going to stop on. Now you're a believer, and you're on a subscription.
People get this one wrong constantly. Patients often assume washing and brushing are making it worse and start avoiding both. Keep washing and styling normally.3 The hair in the brush was already on its way out. Leaving it up there in protest accomplishes nothing.
When It's Something Else
Diffuse thinning all over fits everything above. A few things don't, and those are worth a dermatologist instead of a wait-and-see.
- Round or patchy bald spots with sharp edges, which suggests alopecia areata
- Scaling, itching, burning, or a sore scalp
- Visible scarring, or patches where the skin looks smooth and shiny with no follicle openings
- Shedding that keeps going past six months
- Loss concentrated at the temples or crown in a recognizable pattern, which can be androgenetic alopecia becoming obvious
That last one comes up a lot. A population study of GLP-1 users found the increased risk held across diagnoses, including androgenetic alopecia and telogen effluvium, and the authors were candid that part of the increase could reflect drug effects, metabolic effects, or just more doctor visits producing more diagnoses.4 Pattern hair loss that was already quietly underway gets a lot more visible once overall density drops.
A caveat on that study and the observational work around it. Those cohorts compared GLP-1 users against people not on the drugs, rather than against people losing the same weight some other way, so they can't separate the medication from the weight loss or from obesity itself.45 The randomized trial data in the labels, where the comparison group is a placebo, is the cleaner read.
How We Handle This at Defiant
Every GLP-1 patient here starts with a $50 provider consult, separate from the program cost, and a lab review. We write the orders and you do the draw at your PCP or through Rythm Health, since we don't run blood draws in the clinic. If hair is on your mind at all, iron studies and thyroid are the two to bring up at that visit.
The rest of how we run the program happens to line up with what the literature says about shedding. Titration goes bi-weekly instead of in monthly leaps, which gives a provider more control over how fast the weight comes off. Monthly Styku scans show whether you're losing fat or lean mass, which is the same conversation as protein. And nurse access between visits means you can flag shedding the week it starts instead of sitting on it until your next appointment.
We don't sell a hair loss protocol. Given what the clinical reference says about treating this, we'd have to invent one first.
One clarification on the data above, because it matters and most clinics skip it. The trials and labels cited on this page tested branded, FDA-approved semaglutide and tirzepatide. Compounded versions, which is what many clinics including ours dispense, weren't in those trials and don't carry those labels. Same underlying molecules, and no particular reason to expect a different shedding pattern, but the numbers here come from the branded products and you should hear that from us rather than find it out later.
Defiant is at 5100 Lincoln Ave in Lisle, IL, serving Naperville, Downers Grove, Wheaton, Oak Brook, and Chicago's western suburbs. Our medically supervised weight loss program starts from $295 a month, which covers medication, provider oversight, bi-weekly titration check-ins, monthly body composition scans, and ongoing nurse access.
- Hair loss was reported by 3% of adults on semaglutide versus 1% on placebo, and by 4% to 5% of adults on tirzepatide versus 1% on placebo.12
- The tirzepatide rate doesn't rise with dose, and the label states the hair loss was associated with weight reduction rather than the drug itself.2
- Women reported it far more often than men: 7.1% versus 0.5% on tirzepatide, and 1.3% versus 0% on placebo.2
- The pattern fits telogen effluvium, where stress pushes growing hairs into a resting phase and the shedding shows up about three months later, with a range of one to six months.3
- Acute telogen effluvium lasts under six months by definition, leaves no scarring, and typically recovers on its own once the trigger passes.3
- Enough protein, a slower pace of loss, and checking iron and thyroid are the levers with real support. Topical minoxidil has not been proven to promote recovery in telogen effluvium.3
Frequently Asked Questions
Titrated Every Two Weeks.
How fast the weight comes off is the one lever that touches shedding, and it's a lever a provider should be holding. Our GLP-1 program includes lab review, bi-weekly titration check-ins, monthly Styku scans, and nurse access between visits. From $295 a month.
Keep Reading
Last updated September 18, 2026.
References
- Novo Nordisk. Wegovy (semaglutide) injection Prescribing Information, Section 6.1, Table 3. U.S. FDA, 2026. FDA label
- Eli Lilly and Company. Zepbound (tirzepatide) injection Prescribing Information, Section 6.1, Table 1 and the Hair Loss subsection. U.S. FDA, 2026. FDA label
- Hughes EC, Syed HA, Saleh D. Telogen Effluvium. StatPearls. StatPearls Publishing. Updated May 1, 2024. PubMed (NBK430848)
- Vidal SI, Akiska YM, Nasseri M, et al. Increased risk of hair loss with GLP-1 receptor agonists: A real-world multicenter TriNetX cohort study. JAAD International. 2026;25:133-135. PubMed
- Burke O, Sa B, Alvarez Cespedes D, Sechi A, Tosti A. Glucagon-like peptide-1 receptor agonist medications and hair loss: A retrospective cohort study. Journal of the American Academy of Dermatology. 2025;92(5):1141-1143. PubMed